Literature DB >> 10780035

Reevaluation of continuous oxygen therapy after initial prescription in patients with chronic obstructive pulmonary disease.

Y Oba1, G A Salzman, S K Willsie.   

Abstract

BACKGROUND: Long-term oxygen therapy improves survival and quality of life in hypoxemic patients with chronic obstructive pulmonary disease (COPD). The need for long-term oxygen therapy should be determined when patients are medically stable. The Third Oxygen Consensus Conference recommended reevaluating patients 1-3 months after continuous oxygen therapy (COT) is initiated, if initiated when the patient is medically unstable.
METHODS: A cross-sectional study was performed to examine how often orders for COT are reevaluated pursuant to the guidelines promulgated by the Third Oxygen Therapy Consensus Conference, and to assess the impact that following these guidelines would have on the cost of COT.
RESULTS: Of 226 patients prescribed home oxygen therapy, 92 had COPD as a primary diagnosis and 57 were prescribed COT. Only 19 (35%) of 55 patients who returned to the clinics were appropriately reevaluated. The rate of appropriate reevaluation was significantly higher among pulmonary physicians than among primary care physicians (65% vs 17%; odds ratio: 9.0; 95% confidence interval: 2.5-32). Of 19 patients who were appropriately reevaluated, 11 (58%) were discontinued from COT. The patients who were discontinued from COT had a significantly higher percent of predicted forced expiratory volume in the first second than those who were not (34 +/- 8.6% vs 25 +/- 8.8%; p = 0.04).
CONCLUSIONS: In our study, most patients were clinically unstable when COT was prescribed, and a significant number of patients remained on COT without reevaluation. Up to 60% of those patients could potentially be discontinued from COT if appropriately reevaluated. Referring a patient initiated on COT to a pulmonary specialist for the proper use of oxygen is strongly recommended. Reevaluating such patients in a timely fashion and discontinuing unnecessary oxygen concentrators could possibly save $106-153 million per year in the United States.

Entities:  

Mesh:

Year:  2000        PMID: 10780035

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  6 in total

1.  Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report.

Authors:  Thomas L Croxton; William C Bailey
Journal:  Am J Respir Crit Care Med       Date:  2006-04-13       Impact factor: 21.405

2.  Oxygen therapy use in older adults with chronic obstructive pulmonary disease.

Authors:  Shawn P E Nishi; Wei Zhang; Yong-Fang Kuo; Gulshan Sharma
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

3.  Korean physician prescription patterns for home oxygen therapy in chronic obstructive pulmonary disease patients.

Authors:  Youlim Kim; Hwan Il Kim; Ji Young Park; Ji Young Hong; Joo-Hee Kim; Kyung Hoon Min; Chin Kook Rhee; Sunghoon Park; Chang Youl Lee; Seong Yong Lim; Seung Hun Jang; Yong Il Hwang
Journal:  Korean J Intern Med       Date:  2021-08-20       Impact factor: 2.884

4.  Short-Term Oxygen Therapy Outcomes in COPD.

Authors:  Thibaud Soumagne; François Maltais; François Corbeil; Bruno Paradis; Marc Baltzan; Paula Simão; Araceli Abad Fernández; Richard Lecours; Sarah Bernard; Yves Lacasse
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-07-28

5.  Reassessment of Home Oxygen Prescription after Hospitalization for Chronic Obstructive Pulmonary Disease. A Potential Target for Deimplementation.

Authors:  Laura J Spece; Eric M Epler; Kevin Duan; Lucas M Donovan; Matthew F Griffith; Stephanie LaBedz; Neeta Thakur; Renda Soylemez Wiener; Jerry A Krishnan; David H Au; Laura C Feemster
Journal:  Ann Am Thorac Soc       Date:  2021-03

6.  Long-term oxygen therapy in COPD patients: population-based cohort study on mortality.

Authors:  Nikolay Pavlov; Alan Gary Haynes; Armin Stucki; Peter Jüni; Sebastian Robert Ott
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-03-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.